Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Molecular Magnetic Resonance Imaging in Cardiovascular Medicine

Molecular Magnetic Resonance Imaging in Cardiovascular Medicine New Drugs and Technologies Molecular Magnetic Resonance Imaging in Cardiovascular Medicine David E. Sosnovik, MD; Matthias Nahrendorf, MD; Ralph Weissleder, MD, PhD he ability of magnetic resonance imaging (MRI) to Pharmaceuticals, Lexington, Mass.), gadolinium-containing 6,7 Tevaluate cardiovascular pathophysiology at several lev- high-density lipoprotein–like nanoparticles, gadolinium- els is one of the strengths of the technique. As shown in containing micelles, and gadolinium-containing lipo- 9–11 Figure 1, cardiac phenotype can be assessed at the whole- somes. In addition to longer intravascular half-lives, these organ level by cine MRI, at the regional level with strain, novel gadolinium constructs also have higher longitudinal perfusion, and viability imaging, and at the metabolic level relaxivities (R1). The relaxivity of an MR contrast agent 1,2 with spectroscopic techniques. However, MRI of biological reflects its ability to interact with adjacent protons and processes at the cellular and subcellular level (molecular strongly influences its detectability. The higher the R1 of an MRI) has been studied most extensively in other disease agent, the brighter tissue in its vicinity becomes, whereas the 3,4 states such as cancer. Molecular MRI techniques are, higher the transverse relaxivity (R2), the darker the tissue however, being increasingly developed for cardiovascular becomes. The R1 of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Circulation Wolters Kluwer Health

Molecular Magnetic Resonance Imaging in Cardiovascular Medicine

Weissleder, Ralph
Circulation , Volume 115 (15) – Apr 1, 2007
Download PDF
11 pages

Loading next page...
 
/lp/wolters-kluwer-health/molecular-magnetic-resonance-imaging-in-cardiovascular-medicine-pUW090Emz3

References (114)

ISSN
0009-7322
eISSN
1524-4539
DOI
10.1161/CIRCULATIONAHA.106.658930
pmid
17438163
Publisher site
See Article on Publisher Site

Abstract

New Drugs and Technologies Molecular Magnetic Resonance Imaging in Cardiovascular Medicine David E. Sosnovik, MD; Matthias Nahrendorf, MD; Ralph Weissleder, MD, PhD he ability of magnetic resonance imaging (MRI) to Pharmaceuticals, Lexington, Mass.), gadolinium-containing 6,7 Tevaluate cardiovascular pathophysiology at several lev- high-density lipoprotein–like nanoparticles, gadolinium- els is one of the strengths of the technique. As shown in containing micelles, and gadolinium-containing lipo- 9–11 Figure 1, cardiac phenotype can be assessed at the whole- somes. In addition to longer intravascular half-lives, these organ level by cine MRI, at the regional level with strain, novel gadolinium constructs also have higher longitudinal perfusion, and viability imaging, and at the metabolic level relaxivities (R1). The relaxivity of an MR contrast agent 1,2 with spectroscopic techniques. However, MRI of biological reflects its ability to interact with adjacent protons and processes at the cellular and subcellular level (molecular strongly influences its detectability. The higher the R1 of an MRI) has been studied most extensively in other disease agent, the brighter tissue in its vicinity becomes, whereas the 3,4 states such as cancer. Molecular MRI techniques are, higher the transverse relaxivity (R2), the darker the tissue however, being increasingly developed for cardiovascular becomes. The R1 of

Journal

Circulation – Wolters Kluwer Health

Published: Apr 1, 2007

There are no references for this article.